welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
PTC Therapeutics Announces First-Ever Winners of Its PRIORITY Program To Support Research Projects In Rare, Genetic Disorders
PTC Therapeutics, Inc. today announced the three funding recipients from PRIORITY, an annual program to support outstanding clinical research by the rare genetic disorders community. This year’s funding will accelerate innovative research projects to improve Duchenne muscular dystrophy screening in infants and support earlier diagnosis of this progressive, muscle-wasting disease.
“We were overwhelmed to receive so many outstanding applications in the first year of PRIORITY and to see such a breadth of ideas to improve the screening and diagnosis of Duchenne,” said Dr. Claudio Santos, Senior Vice President, Global Medical Affairs, PTC Therapeutics, Inc. “We are thrilled that the PRIORITY program will help bring these research projects to fruition and ultimately help patients receive the best care as early as possible.”
rareRelated
-
Design of a phase 3 trial to evaluate the long-term efficacy and safety of ataluren in patients with nonsense mutati...Ataluren is conditionally approved by th...
-
Solid Biosciences Announces FDA Lifts Clinical Hold on IGNITE DMD Clinical TrialSolid Biosciences Inc., a life sciences ...
-
Capricor Therapeutics Expands Exosome Technology for DMDCapricor Therapeutics is expanding the d...
-
Open Label Extension Study of HT-100 in Patients With DMDThis study is designed to provide 6-mont...
-
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular DystrophyThe primary objective of this study is t...
-
FDA paves way for clinical trials of Sarepta’s Duchenne MD therapy SRP-5051The U.S. Food and Drug Administration ha...
-
Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double...Background: Duchenne muscular dystrophy...
